All data are based on the daily closing price as of April 22, 2025
p
PharmaEssentia
6446.TW
14.87 USD
-0.32
-2.11%
Overview
Last close
14.87 usd
Market cap
5.07B usd
52 week high
23.57 usd
52 week low
8.76 usd
Target price
21.56 usd
Valuation
P/E
54.5147
Forward P/E
N/A
Price/Sales
16.0419
Price/Book Value
5.7911
Enterprise Value
4.28B usd
EV/Revenue
14.2751
EV/EBITDA
41.0588
Key financials
Revenue TTM
299.62M usd
Gross Profit TTM
263.39M usd
EBITDA TTM
56.84M usd
Earnings per Share
0.27 usd
Dividend
N/A usd
Total assets
867.04M usd
Net debt
-583.77M usd
About
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.